International developed-market equities have drawn attention from investors looking for diversification beyond U.S.-heavy portfolios, along with access to more attractive valuations and higher dividend yields. The IDEV and IEFA comparison stands out because both iShares funds sit in nearly the same “core developed international” space. They do not pursue entirely different strategies but instead provide slightly different slices of the same opportunity set. Understanding differences in index coverage, costs, and sector exposures helps clarify which vehicle aligns better with a long-term allocation to developed markets outside the U.S.
IDEV is a passively managed, market-capitalization-weighted ETF that seeks to track the MSCI World ex USA Investable Market Index. This benchmark covers large-, mid-, and small-cap stocks across developed markets outside the United States. The fund holds roughly 2,250–2,300 securities and carries a net expense ratio of just 0.04%. Its key structural feature is the inclusion of Canada, which accounts for about 11–12% of assets. Top holdings include ASML Holding, HSBC Holdings, AstraZeneca, Novartis, Roche, Nestlé, Royal Bank of Canada, Siemens, Shell, and Toyota, with no single position dominating. Sector weights lean toward Financials (roughly 24%), Industrials (about 18–19%), Health Care (near 9%), and Information Technology (around 9–11%). Japan, the U.K., Canada, and continental Europe rank among the largest geographic weights. I also checked sector breakdowns using Tickeron’s AI Screener to compare this fund with peers.
IEFA is a passively managed, market-capitalization-weighted ETF that tracks the MSCI EAFE IMI Index, covering large-, mid-, and small-cap equities in Europe, Australasia, and the Far East. The fund holds roughly 2,600 securities and charges a net expense ratio of 0.07%. Unlike IDEV, it excludes both the United States and Canada, concentrating exposure in Japan (roughly 24–26%), the U.K. (about 14%), France, Switzerland, Germany, and Australia. Top holdings include ASML Holding, HSBC Holdings, Roche, Shell, Novartis, AstraZeneca, Mitsubishi UFJ Financial Group, Nestlé, Siemens, and BHP. Sector weights favor Financials (about 23%), Industrials (roughly 20%), Health Care (near 10%), and Consumer Discretionary (around 9%). From what I see, this gives the fund a pronounced value-cyclical character relative to U.S. benchmarks.
Both funds operate in the same broad environment. Non-U.S. developed markets have benefited in recent cycles from cheaper valuations, higher dividend yields, and the prospect of easing monetary policy in Europe and Japan. Japanese corporate-governance reforms and share-buyback momentum have supported returns, while European industrials and financials have attracted flows tied to defense spending, infrastructure investment, and a steeper yield curve. At the same time, both ETFs remain sensitive to currency swings, global trade dynamics, and earnings cycles in semiconductors, pharmaceuticals, and banking. Sector concentration in Financials and Industrials means both carry a cyclical tilt that can amplify drawdowns during slowdowns but support stronger participation in recoveries. I reviewed recent trend signals on these holdings through Tickeron’s AI Trend Prediction Engine for additional context.
Over recent weeks and months, IDEV and IEFA have moved closely together, reflecting their near-identical developed-market exposure and overlapping top holdings. Divergences have been driven mainly by two structural factors. IDEV’s Canadian allocation, dominated by banks and energy producers, has shaped its sector exposure and sensitivity to oil prices and North American credit conditions. IEFA’s exclusion of Canada concentrates weights more heavily in Japan and Europe, making it somewhat more responsive to eurozone and yen-denominated trends. Volatility levels are broadly comparable, though IDEV’s slightly broader geographic base and lower cost may offer a marginal long-term edge. Neither fund has shown a decisive performance advantage in recent cycles; differences remain structural rather than directional.
When comparing these two ETFs, I often turn to Tickeron’s AI-powered tools to scan for comparable holdings and test sector exposures across broader universes. The platform’s customizable filters for fundamentals, technical patterns, and volatility help surface nuances that manual review might miss. In this case, the data reinforced the structural advantages I noted earlier without altering the core conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IEFA advanced for three days, in 264 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 61 cases where IEFA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for IEFA just turned positive on October 16, 2026. Looking at past instances where IEFA's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
IEFA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IEFA as a result. In 65 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IEFA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for IEFA entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Category ForeignLargeBlend